MA30501B1 - Composition pharmaceutique stable contenant du docetaxel et son procede de preparation. - Google Patents

Composition pharmaceutique stable contenant du docetaxel et son procede de preparation.

Info

Publication number
MA30501B1
MA30501B1 MA31456A MA31456A MA30501B1 MA 30501 B1 MA30501 B1 MA 30501B1 MA 31456 A MA31456 A MA 31456A MA 31456 A MA31456 A MA 31456A MA 30501 B1 MA30501 B1 MA 30501B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
containing docetaxel
stable pharmaceutical
preparation
preparing
Prior art date
Application number
MA31456A
Other languages
English (en)
Inventor
Nam Ho Kim
Jin Young Lee
Jae-Sun Kim
Nam Kyu Lee
Woo Jae Jang
Joon Gyo Oh
Yoon-Jung Lee
Woong Sik Kim
Jin-Heung Sung
Key An Um
Original Assignee
Sk Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39090946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30501(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sk Chemicals Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of MA30501B1 publication Critical patent/MA30501B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique stable pour injection contenant du docétaxel et son procédé de préparation. Plus particulièrement, la présente invention concerne une composition pharmaceutique pour injection contenant du docétaxel et présentant une stabilité au stockage améliorée par comparaison avec les médicaments classiques. La préparation de cette composition consiste à dissoudre du docétaxel, un composé hydro-insoluble, dans de l'eau distillée après son mélange avec de la cyclodextrine (CD) et un polymère hydrosoluble tel que l'hydroxypropyl méthylcellulose (HPMC), le polyéthylène glycol (PEG) ou la polyvinylpyrrolidone (PVP), puis à lyophiliser le mélange. L'invention concerne également un procédé de préparation de cette composition.
MA31456A 2006-05-22 2008-12-05 Composition pharmaceutique stable contenant du docetaxel et son procede de preparation. MA30501B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20060045715 2006-05-22
KR1020070049340A KR100917809B1 (ko) 2006-05-22 2007-05-21 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물

Publications (1)

Publication Number Publication Date
MA30501B1 true MA30501B1 (fr) 2009-06-01

Family

ID=39090946

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31456A MA30501B1 (fr) 2006-05-22 2008-12-05 Composition pharmaceutique stable contenant du docetaxel et son procede de preparation.

Country Status (25)

Country Link
US (1) US8791152B2 (fr)
EP (1) EP2019664B1 (fr)
JP (1) JP5369332B2 (fr)
KR (2) KR100917809B1 (fr)
CN (1) CN101484137B (fr)
AU (1) AU2007252371B2 (fr)
BR (1) BRPI0711893A2 (fr)
CA (1) CA2653124C (fr)
CR (1) CR10485A (fr)
EA (1) EA014071B1 (fr)
EC (1) ECSP088951A (fr)
ES (1) ES2560641T3 (fr)
GE (1) GEP20115200B (fr)
GT (1) GT200800257A (fr)
HK (1) HK1128874A1 (fr)
IL (1) IL195459A (fr)
MA (1) MA30501B1 (fr)
MX (1) MX2008014948A (fr)
MY (1) MY149627A (fr)
NO (1) NO20084932L (fr)
NZ (1) NZ573202A (fr)
SV (1) SV2008003106A (fr)
TN (1) TNSN08475A1 (fr)
WO (1) WO2007136219A1 (fr)
ZA (1) ZA200809998B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102516417B (zh) 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2146695A4 (fr) * 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd Compositions pharmaceutiques
KR101502533B1 (ko) * 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
EP2853264A1 (fr) * 2007-12-24 2015-04-01 Sun Pharma Advanced Research Company Limited Nanodispersion
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
WO2010146606A1 (fr) 2009-06-19 2010-12-23 Sun Pharma Advanced Research Company Ltd., Nanodispersion d'un médicament et son procédé de préparation
JP5855568B2 (ja) * 2009-09-15 2016-02-09 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
EA201200617A1 (ru) 2009-11-23 2012-11-30 Серулин Фарма Инк. Полимеры на основе циклодекстрина для доставки лекарственных средств
CA2798180A1 (fr) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Formulations non aqueuses de pro-emulsions a base de taxane et procedes de fabrication et d'utilisation de ces formulations
KR20120130740A (ko) * 2011-05-23 2012-12-03 에스케이케미칼주식회사 도세탁셀을 함유하는 액상 주사용 조성물
WO2012161520A2 (fr) * 2011-05-23 2012-11-29 에스케이케미칼 주식회사 Composition liquide injectable contenant du docétaxel
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
WO2014055493A1 (fr) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Procédés et systèmes s'appliquant à la précipitation de polymères et à la génération de particules
EP2777691A1 (fr) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoïde - purification des excipients liquides
KR20140147336A (ko) * 2013-06-19 2014-12-30 에스케이케미칼주식회사 도세탁셀을 함유하는 액상 주사용 조성물
US10413517B2 (en) * 2014-06-12 2019-09-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
CN107427486B (zh) * 2015-03-16 2020-07-10 湖南省金准医疗科技有限公司 含有紫杉烷-环糊精复合物的药物组合物、制造方法和使用方法
EP3364947B1 (fr) 2015-10-20 2021-09-15 B. Braun Melsungen AG Composition aqueuse comprenant dantrolène
WO2018047074A1 (fr) * 2016-09-07 2018-03-15 Cadila Healthcare Limited Compositions stériles injectables comprenant médicament micellaires
CN113559277B (zh) * 2018-01-11 2023-11-17 比卡生物科技（广州）有限公司 一种注射用卡巴他赛组合物及其制备方法
JP7274785B2 (ja) * 2018-07-25 2023-05-17 ビカ バイオテクノロジー （グアンジョウ） カンパニー リミテッド 注射用ドセタキセル組成物およびそのための調製法
CN111603387A (zh) * 2020-06-03 2020-09-01 芜湖市第二人民医院 一种多西他赛注射液存储装置及其配制方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003748A1 (fr) * 1991-08-13 1993-03-04 Temple University - Of The Commonwealth System Of Higher Education Modulation de la tension arterielle et inhibition de l'activation plaquettaire a l'aide d'un fragment de kininogene
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
HUT73844A (en) * 1994-11-11 1996-09-30 Chinoin Gyogyszer Es Vegyeszet New taxol complexes and pharmaceutical compositions containing them
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
US6133473A (en) * 1998-06-25 2000-10-17 Rohm And Haas Company Synthesis of carbamate compounds
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
KR100310839B1 (ko) 1999-03-23 2001-10-12 정기련 안정성이 개선된 파크리탁셀 가용화 주사제 조성물
MXPA01011981A (es) 1999-05-24 2003-09-04 Sonus Pharma Inc Vehiculo de emulsion para farmacos poco solubles.
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
IL146659A0 (en) * 1999-05-27 2002-07-25 Acusphere Inc Porous drug matrices and method of manufacture thereof
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US20040253315A1 (en) * 2001-07-13 2004-12-16 Yasuaki Ogawa Lyophilizing composition of drug-encapsulating polymer micelle and method for preparation thereof
KR20030041577A (ko) * 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
JP2003342168A (ja) * 2002-05-24 2003-12-03 Nano Career Kk 注射用薬物含有ポリマーミセル製剤の製造方法
US20050255164A1 (en) * 2002-08-15 2005-11-17 Yunging Liu Solid nano pharmaceutical formulation and preparation method thereof
CN1502332A (zh) * 2002-11-25 2004-06-09 刘云清 抗癌药紫杉醇自乳化固体纳米粒——注射用紫杉醇的制备方法
US20040127551A1 (en) 2002-12-27 2004-07-01 Kai Zhang Taxane-based compositions and methods of use
JP2005075783A (ja) 2003-09-01 2005-03-24 Otsuka Pharmaceut Factory Inc 難溶性化合物の可溶化または分散化用組成物
CN101137395B (zh) * 2005-03-14 2012-10-31 株式会社大塚制药工场 含有水难溶性药物的医药组合物

Also Published As

Publication number Publication date
ZA200809998B (en) 2009-11-25
NZ573202A (en) 2010-08-27
CA2653124C (fr) 2014-04-22
GEP20115200B (en) 2011-04-11
KR100917809B1 (ko) 2009-09-18
IL195459A (en) 2013-09-30
EP2019664A1 (fr) 2009-02-04
WO2007136219A1 (fr) 2007-11-29
GT200800257A (es) 2010-10-19
KR100983376B1 (ko) 2010-09-20
KR20070112725A (ko) 2007-11-27
EP2019664B1 (fr) 2016-01-06
SV2008003106A (es) 2010-04-30
JP2009538294A (ja) 2009-11-05
AU2007252371B2 (en) 2013-07-25
EA200870559A1 (ru) 2009-04-28
US20090163574A1 (en) 2009-06-25
EA014071B1 (ru) 2010-08-30
TNSN08475A1 (en) 2010-04-14
ECSP088951A (es) 2009-02-27
EP2019664A4 (fr) 2013-03-13
BRPI0711893A2 (pt) 2012-01-10
JP5369332B2 (ja) 2013-12-18
CR10485A (es) 2009-03-02
HK1128874A1 (zh) 2009-11-13
IL195459A0 (en) 2009-08-03
CA2653124A1 (fr) 2007-11-29
ES2560641T3 (es) 2016-02-22
US8791152B2 (en) 2014-07-29
MY149627A (en) 2013-09-13
NO20084932L (no) 2008-12-19
KR20090101145A (ko) 2009-09-24
MX2008014948A (es) 2009-02-03
CN101484137A (zh) 2009-07-15
AU2007252371A1 (en) 2007-11-29
CN101484137B (zh) 2014-05-14

Similar Documents

Publication Publication Date Title
MA30501B1 (fr) Composition pharmaceutique stable contenant du docetaxel et son procede de preparation.
MA30500B1 (fr) Imidazolones et triazolones d'aryle substitues comme inhibiteurs des recepteurs de vasopressine.
RU2006143666A (ru) Фармацевтические композиции в виде раствора, содержащие 17-aag
AU772204B2 (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method
WO2009066955A3 (fr) Composition pharmaceutique lyophilisée à stabilité améliorée contenant des dérivés de taxane, et procédé de préparation correspondant
RU2006147247A (ru) Фармацевтические композиции
JP5087086B2 (ja) シクロデキストリン・パクリタクセルの包接体を含有する薬物組成物及びその製造方法
CA2277878A1 (fr) Comprimes a delitement rapide
WO2004071502A1 (fr) Formulation liquide injectable de paracetamol
JP2013545819A (ja) 非経口投与のためのアゾール医薬製剤ならびにその調製方法およびアゾール化合物に対して感受性の疾患の処置としてのその使用方法
KR20110098906A (ko) 피노셈브린과 사이클로덱스트린 또는 그의 유도체와의 포접 화합물
CH660302A5 (fr) Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
CN1795014A (zh) 分子络合物的制备方法
LU82360A1 (fr) Compositions injectables a base d'oxytetracycline
JP5157447B2 (ja) メキタジンとシクロデキストリンと相互作用剤を含む複合体
US11382871B2 (en) Pharmaceutical composition containing curcumin
CN1290506C (zh) 药物组合物
EP0269598A1 (fr) Agents thérapeutiques contre la leishmaniose
US7157446B2 (en) Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
UA93249C2 (uk) Стабільна фармацевтична композиція, яка містить доцетаксел, і спосіб виготовлення такої композиції
CA2100836E (fr) Composition pharmaceutique
EP2066301A1 (fr) Solutions pharmaceutiques injectables de nimésulide
US20060263327A1 (en) Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances
WO2000067727A1 (fr) Formulations galeniques d'agents antithrombiotques pour administration sous-cutanee
EP0692249A1 (fr) Composés comportant une ou plusieurs fonctions oximes, stabilisés en solution aqueuse, leur procédé d'obtention, et leur utilisation en tant que médicaments